Back to search

Article

Plerixafor Engages β-Arrestin–Dependent CXCR4 Signaling to Promote Melanogenesis via β-Catenin–MITF Activation

2026-06-02

Abstract excerpt

Plerixafor is a clinically approved CXCR4 antagonist that mobilizes hematopoietic stem cells by disrupting CXCL12/CXCR4 retention signaling. However, its biochemical effects on melanocytes and pigmentation remain unexplored. We investigated how plerixafor modulates CXCR4 sig-naling in melanocytes and evaluated its potential as a pro-melanogenic agent using in vitro and in vivo approaches. Human PIG1 melanocytes we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ebb21f3e-a5cf-529e-aa8d-e1d9b51a420c
DOI
10.20944/preprints202603.1777.v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Plerixafor Engages β-Arrestin–Dependent CXCR4 Signaling to Promote Melanogenesis via β-Catenin–MITF ActivationDOI 10.20944/preprints202603.1777.v2
Select a neighboring publication to make it the new centre.